Phaseline

Targets › CD138

CD138: drug programs, companies and trials

3 programs from 3 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on CD138, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The First Affiliated Hospital of Soochow UniversityCART-138/BCMA/19/more
Multi-antigen CAR-T cell therapy targeting CD138, BCMA (TNFRSF17), CD19, and additional an
CD138, TNFRSF17, CD19Phase 1Multiple MyelomaDec 2026
Nammi TherapeuticsQXL138AM
Anti-CD138 IgG1 antibody fused to human interferon alpha 2a
CD138Phase 1Ovarian CancerDec 2027
UNC Lineberger Comprehensive Cancer CenterATLCAR.CD138
anti-CD138 CAR-T cell therapy
CD138Phase 1Multiple MyelomaAug 2039

Conditions

Multiple Myeloma (2) Ovarian Cancer (1)

Modalities

other (2), protein or peptide (1)

Companies

UNC Lineberger Comprehensive Cancer Center (1) Nammi Therapeutics (1) The First Affiliated Hospital of Soochow University (1)

Related targets

TNFRSF17 (1) CD19 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.